Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 25 of 874

TitleReference numberPublishedLast updated
Avelumab with axitinib for untreated advanced renal cell carcinomaTA1120
Entrectinib for treating NTRK fusion-positive solid tumours in people 12 years and over (terminated appraisal)TA1118
Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemiaTA1119
Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiencyTA1117
Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemiaTA1116
Vutrisiran for treating transthyretin amyloidosis with cardiomyopathyTA1115
Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphomaTA1113
Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatmentsTA1114
Abiraterone (originator and generics) for treating newly diagnosed high-risk hormone‑sensitive metastatic prostate cancerTA1110
Nintedanib for treating fibrosing interstitial lung disease in people 6 to 17 years (terminated appraisal)TA1111
Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (terminated appraisal)TA1112
Darolutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancerTA1109
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancerTA1108
Cabotegravir for preventing HIV-1 in adults and young peopleTA1106
Delgocitinib for treating moderate to severe chronic hand eczemaTA1107
Iptacopan for treating complement 3 glomerulopathy (terminated appraisal)TA1102
Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal)TA1104
Clascoterone for treating acne vulgaris in people 12 years and over (terminated appraisal)TA1105
Lorlatinib for ALK-positive advanced non-small-cell lung cancer that has not been treated with an ALK inhibitorTA1103
Sparsentan for treating primary IgA nephropathyTA1074
Targeted-release budesonide for treating primary IgA nephropathyTA937
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and overTA1101
Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapyTA1099
Mirabegron for treating neurogenic detrusor overactivity in people 3 to 17 years (terminated appraisal)TA1100
Isatuximab in combination for untreated multiple myeloma when a stem cell transplant is unsuitableTA1098

Results per page

  1. 10
  2. 25
  3. 50
  4. All